Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
Back
EBCL-0026
Investigational drugs are compounds that have been approved for testing in clinical trials. They have verified structure, manufacturing process, and quality control protocols as well as passed preliminary animal studies. Clinical trials will check if potential drugs work effectively and safely on humans. Compounds, successively passed all phases of clinical trials, can be submitted for FDA (or other pharmaceutical regulatory agency) approval to become a new drug.
The library of Investigational Drugs consists of 875 compounds that entered the first phase of clinical trials. All information about national clinical trial (NCT) numbers and annotated biological activity is also available.
Related terms: epidermal growth factor receptor, MET proto-oncogene, receptor tyrosine kinase, AKT serine/threonine kinase, aurora kinase A, mitogen-activated protein kinase
Zorifertinib is a potent, orally active, central nervous system-penetrant, EGFR inhibitor with IC50= 0.5 nM
Presatovir (GS-5806) is a RSV fusion inhibitor.
Dapansutrile inhibits the NLRP3 inflammasome. It has anti-inflammatory, analgesic activity.
TAK-901 has antineoplastic activity. It is a multi-targeted aurora inhibitor (aurora A and B).
We propose the complete list of Services powered by Enamine
All our products are for research purpose only. Any personal or non-scientific use is strictly prohibited.
NoteAll the compounds with solubility below 10 mM are shipped as 2 mM solutions.
epidermal growth factor receptor
20
20
Number of compounds
20
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
16
16
Number of compounds
16
MET proto-oncogene, receptor tyrosine kinase
16
16
Number of compounds
16
kinase insert domain receptor
15
15
Number of compounds
15
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
12
12
Number of compounds
12
© 2026 Copyright Enamine